CD274 and urothelial carcinoma: The median OS of 10.97 mo for patients with advanced urothelial carcinoma following second-line anti–PD-(L)1 treatment was similar to that reported in studies of second-line anti–PD-(L)1 therapy (eg, 10.3 mo for pembrolizumab [28], 8.7 mo for nivolumab [29], and 11.1 mo for atezolizumab) [6].